Travere Therapeutics, Inc.
TVTX· Nasdaq
TVTXTravere Therapeutics, Inc.
Filed Feb 20, 2024 · 10-K · 51 days after period end · 0001438533-24-000005
| Metric | Q4 2023 | Q4 2022 | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $45.06M | $29.34M | — | $50.98M |
| Net Income | -$90.17M | -$65.82M | -$51.57M | -$121.62M |
| EPS Diluted | -$1.18 | -$1.03 | — | -$2.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 20, 2024 · 51 d after period end
